Amgen stock ends the day 3.36 percent higher at USD 406.37
Published on 09/22/2026 at 23:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock closed at USD 406.37 on the Nasdaq on September 22, 2026, gaining 3.36 percent from the prior close. The move followed positive topline Phase 3 results for dazodalibep in Sjogren's disease, as Investing.com reported.
September 22, 2026 in numbers
Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) added USD 13.21 during the session, according to the closing report from JKN. The report attributed the gain to successful topline Phase 3 results for dazodalibep, which met the primary endpoint and showed improvement in systemic disease activity at Week 48.
The trial enrolled approximately 621 patients, and the company plans to present detailed data at an upcoming medical meeting, according to Investing.com. The regular-session close was the main U.S. market reference for the stock after the Nasdaq session ended at 4:00 p.m. ET.
Dazodalibep data after the bell today
Amgen has said detailed OASIZ 301 data will be presented at an upcoming medical meeting, while the OASIZ 303 study is expected to complete in the fourth quarter of 2026, according to Investing.com. Those study milestones give the next trading session a company-specific clinical-data focus.
